Sanofi/Regeneron muscle ahead of a rival Novartis/Roche team, win first approval in key rhinosinusitis field
Regeneron and their partners at Sanofi have beat the Novartis/Roche team to the punch on another key indication for their blockbuster anti-inflammatory drug Dupixent. The drug team scored an accelerated FDA approval for chronic rhinosinusitis with nasal polyps, making this the first such NDA for the field.
Analysts have been watching this race for a while now, as Sanofi/Regeneron won a snap priority review for what is now their third disease indication for this treatment. And they’re not nearly done, building up hopes for a major franchise.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.